AbbVie Inc. and ACADIA Pharmaceuticals Inc.: A Comprehensive Revenue Analysis

Biopharma Revenue Trends: AbbVie vs. ACADIA (2014-2023)

__timestamp	ACADIA Pharmaceuticals Inc.	AbbVie Inc.
Wednesday, January 1, 2014	120000	19960000000
Thursday, January 1, 2015	61000	22859000000
Friday, January 1, 2016	17331000	25638000000
Sunday, January 1, 2017	124901000	28216000000
Monday, January 1, 2018	223807000	32753000000
Tuesday, January 1, 2019	339076000	33266000000
Wednesday, January 1, 2020	441755000	45804000000
Friday, January 1, 2021	484145000	56197000000
Saturday, January 1, 2022	517235000	58054000000
Sunday, January 1, 2023	726437000	54318000000
Monday, January 1, 2024		56334000000

Cracking the code

A Tale of Two Biopharma Giants: Revenue Trends from 2014 to 2023

In the dynamic world of biopharmaceuticals, revenue growth is a key indicator of a company's success and market influence. Over the past decade, AbbVie Inc. and ACADIA Pharmaceuticals Inc. have showcased contrasting revenue trajectories. AbbVie, a titan in the industry, has consistently demonstrated robust growth, with its revenue peaking at approximately $58 billion in 2022, marking a 190% increase from 2014. In contrast, ACADIA Pharmaceuticals, while smaller in scale, has shown impressive growth, with its revenue surging by over 6000% from 2014 to 2023, reaching around $726 million. This stark difference highlights the diverse strategies and market positions of these companies. As we look to the future, these trends offer valuable insights into the evolving landscape of the biopharmaceutical sector.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025